Novavax Developing Coronavirus Vaccine Candidate, Company Says

Jan. 21, 2020, 7:41 PM

Novavax is working on a vaccine candidate in response to the coronavirus sweeping across China and now thought to have reached the U.S., the company said in an email. The vaccine developer shares rallied as much as 67%, the most intraday in more than 10 years, as fears of global contagion spread.

  • NVAX plans to use recombinant nanoparticle vaccine technology for a vaccine candidate, a third party spokeswoman said via email
    • NVAX’s Matrix-M platform will be used to bolster potential immune responses
  • Meanwhile, not everyone was optimistic, with a B Riley FBR analyst saying there’s “more questions than answers on ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.